Delcath Systems (NASDAQ: DCTH) operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. For more information, visit the company’s website at www.delcath.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net